A GLP-1 weight loss pill, already on sale in the United States, has hit a regulatory snag.
The Food and Drug Administration has asked U.S. drugmaker Eli Lilly to collect more long-term safety data on its once-daily tablet Foundayo, according to an April 1 letter published by the FDA Tuesday.